Fulvestrant

Form: Injection

Strength: 250 mg/5 mL

Reference Brands: Faslodex® (EU & US)

Category: Oncology Cancer Care

Fulvestrant is a potent estrogen receptor antagonist used in the treatment of HR+ metastatic breast cancer in postmenopausal women. It is indicated for patients whose cancer has progressed after prior endocrine therapy. Marketed as Faslodex®, Fulvestrant is available in both the US and EU as a 250 mg/5 mL intramuscular injection, typically administered as 500 mg monthly. It works by binding and degrading estrogen receptors, thereby inhibiting cancer cell growth. Widely used in oncology hospitals and cancer centers, Fulvestrant is a valuable product for B2B pharmaceutical distribution in the oncology and specialty injectable segments.